Volume 73, Issue 1, Pages (January 2018)

Slides:



Advertisements
Similar presentations
V. Scattoni mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?
Advertisements

Volume 56, Issue 5, Pages (November 2009)
The PSA Era is not Over for Prostate Cancer
Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.
Volume 71, Issue 6, Pages (June 2017)
Volume 69, Issue 3, Pages (March 2016)
Contemporary Clinical Trials
Volume 57, Issue 1, Pages (January 2010)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 52, Issue 3, Pages (September 2007)
Testosterone Therapy in Men With Prostate Cancer
Volume 56, Issue 6, Pages (December 2009)
Volume 72, Issue 6, Pages (December 2017)
Volume 191, Issue 6, Pages (June 2014)
Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer  Marisa Warmuth,
Volume 74, Issue 4, Pages (October 2018)
Volume 67, Issue 4, Pages (April 2015)
Volume 63, Issue 1, Pages (January 2013)
Volume 67, Issue 3, Pages (March 2015)
Volume 64, Issue 4, Pages (October 2013)
Prostate Cancer Epidemic in Sight?
Volume 65, Issue 6, Pages (June 2014)
Volume 66, Issue 1, Pages (July 2014)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 54, Issue 4, Pages (October 2008)
Elizabeth K. Bancroft, Rosalind A. Eeles
Volume 52, Issue 3, Pages (September 2007)
Volume 69, Issue 3, Pages (March 2016)
European Urology Oncology
Volume 389, Issue 10071, Pages (February 2017)
Prostate Cancer Detection: A View of the Future
Volume 70, Issue 4, Pages (October 2016)
Volume 62, Issue 6, Pages (December 2012)
Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions  Anwar R. Padhani, Jeffrey Weinreb, Andrew.
Prostate Cancer Epidemic in Sight?
Volume 72, Issue 6, Pages (December 2017)
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 68, Issue 6, Pages (December 2015)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 65, Issue 6, Pages (June 2014)
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 68, Issue 4, Pages (October 2015)
Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer  Valeria.
Volume 65, Issue 4, Pages (April 2014)
Volume 68, Issue 6, Pages (December 2015)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 66, Issue 3, Pages (September 2014)
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
European Urology Oncology
European Urology Oncology
Testicular Cancer Variations in Time and Space in Europe
Volume 53, Issue 1, Pages (January 2008)
Volume 75, Issue 4, Pages (April 2019)
Volume 65, Issue 3, Pages (March 2014)
European Urology is “Your” Journal
Volume 75, Issue 4, Pages (April 2019)
Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.
Volume 69, Issue 1, Pages (January 2016)
The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy  Neal Patel, Eliza Cricco-Lizza,
Economic Burden of Bladder Cancer Across the European Union
Volume 389, Issue 10071, Pages (February 2017)
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Systematic Review of Complications of Prostate Biopsy
Volume 54, Issue 3, Pages (September 2008)
Volume 51, Issue 5, Pages (May 2007)
Rita Faria, MSc Centre for Health Economics University of York, UK
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
European Urology Oncology
Presentation transcript:

Volume 73, Issue 1, Pages 23-30 (January 2018) Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS)  Rita Faria, Marta O. Soares, Eldon Spackman, Hashim U. Ahmed, Louise C. Brown, Richard Kaplan, Mark Emberton, Mark J. Sculpher  European Urology  Volume 73, Issue 1, Pages 23-30 (January 2018) DOI: 10.1016/j.eururo.2017.08.018 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Schematic of decision tree. The diagram represents the decision tree used to predict the outcomes of the diagnostic strategies. The diagram shows only the general structure of the tree for diagnostic strategies composed of MPMRI and TRUSB; a similar tree was used for strategies including TPMB. In the model, men can have a sequence of up to three tests. The black lines represent the possible test classifications. The red lines with a question mark represent decisions. Different decisions constitute different sequences of tests and hence different strategies. The diagram highlights strategies M7 (left side) and T7 (right side). In M7, men receive MPMRI and are classified as having no suspicion of cancer (no cancer; NC), suspicion of non-CS cancer, or suspicion of CS cancer. Men with a suspicion of CS cancer receive an MRI-targeted TRUSB, and are classified as having no cancer (NC), non-CS cancer, and CS cancer. Men in whom CS cancer was not detected, but had a suspicion of CS cancer at the MPMRI, receive a second MRI-targeted biopsy. In T7, men receive a TRUSB, and are classified as having no cancer (NC), non-CS cancer, and CS cancer. Men in whom CS cancer was not detected receive an MPMRI, and are classified as having no suspicion of cancer (NC), suspicion of non-CS cancer, or suspicion of CS cancer. Men classified as having a suspicion of CS cancer based on MPMRI results receive a second TRUSB—this time MRI-targeted TRUSB since there is now information from the MPMRI. CS=clinically significant; MPMRI=multiparametric magnetic resonance imaging; TPMB=template mapping biopsy; TRUSB=transrectal ultrasound-guided biopsy. European Urology 2018 73, 23-30DOI: (10.1016/j.eururo.2017.08.018) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 (A) Detection of CS cancers per pound spent in diagnosis. (B) Quality-adjusted life years (QALYs) per NHS spend. Each bubble represents one of the 383 diagnostic strategies evaluated; their size is directly related to the probability that the strategy is cost effective and therefore forms the frontier (ie, forms the red line). The red bubbles represent the 14 diagnostic strategies that form the frontier at expected values. This means that, on average, these are the best strategies per pound spent. The black bubbles represent the strategies that do not form the frontier at expected values, but that have some probability of being in the frontier given their distribution of costs and outcomes. The grey bubbles represent the strategies that do not form the efficiency frontier at any simulation. Given the distribution of parameter inputs, these strategies are never efficient or cost effective. CS=clinically significant; NHS=National Health Service. European Urology 2018 73, 23-30DOI: (10.1016/j.eururo.2017.08.018) Copyright © 2017 European Association of Urology Terms and Conditions